Expression of monocyte chemotactic protein-1/CCL2 in gastric cancer and its relationship with tumor hypoxia

World Journal of Gastroenterology

Volumn 20, Issue 15, 2014, Pages 4421-4427

  Tao, Lei Lei ^a   Shi, Shu Jing ^a   Chen, Long Bang ^a   Huang, Gui Chun ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Chemokines; Gastric cancer; Immunohistochemistry; Monocyte chemotactic protein 1 CCL2; Prognostic marker

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; CCL2 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PROGNOSIS; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PROTEIN EXPRESSION; STOMACH CANCER; SURVIVAL TIME; AGED; ANOXIA; CARCINOMA; GENE EXPRESSION REGULATION; KAPLAN MEIER METHOD; METABOLISM; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STOMACH TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ANOXIA; CARCINOMA; CHEMOKINE CCL2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84898879930     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i15.4421     Document Type: Article

References (26)

1. de Martel C, Forman D, Plummer M. Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am 2013; 42: 219-240 [PMID: 23639638 DOI: 10.1016/j.gtc.2013.01.003]
2. Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. J Surg Oncol 2013; 107: 230-236 [PMID: 23129495 DOI: 10.1002/jso.23262]
3. Kumar RK, Shankar EM, Ganapathy E, Raj SS, Ebrahim AS, Farooq SM. Gastric Carcinoma: A review on epidemiology, current surgical & chemotherapeutic options. In: Lazǎr D, editor. Gastric Carcinoma-New Insights into Current Management. Croatia: InTech, 2013
4. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009; 107: 1053-1062 [PMID: 19479945 DOI: 10.1002/jcb.22214]
5. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26: 225-239 [PMID: 17440684 DOI: 10.1007/s10555-007-9055-1]
6. Adams JM, Difazio LT, Rolandelli RH, Luján JJ, Haskó G, Csóka B, Selmeczy Z, Németh ZH. HIF-1: a key mediator in hypoxia. Acta Physiol Hung 2009; 96: 19-28 [PMID: 19264039 DOI: 10.1556/APhysiol.96.2009.1.2]
7. Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol 2013; 228: 1404-1412 [PMID: 23065796 DOI: 10.1002/jcp.24260]
8. Riboldi E, Porta C, Morlacchi S, Viola A, Mantovani A, Sica A. Hypoxia-mediated regulation of macrophage functions in pathophysiology. Int Immunol 2013; 25: 67-75 [PMID: 23179187 DOI: 10.1093/intimm/dxs110]
9. Ferreira FO, Ribeiro FL, Batista AC, Leles CR, de Cássia Gonçalves Alencar R, Silva TA. Association of CCL2 with lymph node metastasis and macrophage infiltration in oral cavity and lip squamous cell carcinoma. Tumour Biol 2008; 29: 114-121 [PMID: 18525219 DOI: 10.1159/000137669]
10. Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 2010; 21: 41-48 [PMID: 20005149 DOI: 10.1016/j.cytogfr.2009.11.009]
11. Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007; 26: 281-290 [PMID: 17603752 DOI: 10.1007/s10555-007-9066-y]
12. Rohwer N, Lobitz S, Daskalow K, Jöns T, Vieth M, Schlag PM, Kemmner W, Wiedenmann B, Cramer T, Höcker M. HIF-1alpha determines the metastatic potential of gastric cancer cells. Br J Cancer 2009; 100: 772-781 [PMID: 19223895 DOI: 10.1038/sj.bjc.6604919]
13. Siveen KS, Kuttan G. Role of macrophages in tumour progression. Immunol Lett 2009; 123: 97-102 [PMID: 19428556 DOI: 10.1016/j.imlet.2009.02.011]
14. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009; 29: 313-326 [PMID: 19441883 DOI: 10.1089/jir.2008.0027]
15. Bosco MC, Puppo M, Pastorino S, Mi Z, Melillo G, Massazza S, Rapisarda A, Varesio L. Hypoxia selectively inhibits monocyte chemoattractant protein-1 production by macrophages. J Immunol 2004; 172: 1681-1690 [PMID: 14734750]
16. Mojsilovic-Petrovic J, Callaghan D, Cui H, Dean C, Stanimirovic DB, Zhang W. Hypoxia-inducible factor-1 (HIF-1) is involved in the regulation of hypoxia-stimulated expression of monocyte chemoattractant protein-1 (MCP-1/CCL2) and MCP-5 (Ccl12) in astrocytes. J Neuroinflammation 2007; 4: 12 [PMID: 17474992 DOI: 10.1186/1742-2094-4-12]
17. Wang H, Zhang L, Zhang IY, Chen X, Da Fonseca A, Wu S, Ren H, Badie S, Sadeghi S, Ouyang M, Warden CD, Badie B. S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages. Clin Cancer Res 2013; 19: 3764-3775 [PMID: 23719262 DOI: 10.1158/1078-0432. CCR-12-3725]
18. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski TF. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009; 69: 3077-3085 [PMID: 19293190 DOI: 10.1158/0008-5472.CAN-08-2281]
19. Arnold JM, Huggard PR, Cummings M, Ramm GA, Chenevix-Trench G. Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma. Br J Cancer 2005; 92: 2024-2031 [PMID: 15900302 DOI: 10.1038/ sj.bjc.6602596]
20. Wu HH, Lee TH, Tee YT, Chen SC, Yang SF, Lee SK, Ko JL, Wang PH. Relationships of single nucleotide polymorphisms of monocyte chemoattractant protein 1 and chemokine receptor 2 with susceptibility and clinicopathologic characteristics of neoplasia of uterine cervix in Taiwan women. Reprod Sci 2013; 20: 1175-1183 [PMID: 23427179 DOI: 10.1177/19337 19113477481]
21. Fujimoto H, Sangai T, Ishii G, Ikehara A, Nagashima T, Miyazaki M, Ochiai A. Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer 2009; 125: 1276-1284 [PMID: 19479998 DOI: 10.1002/ijc.24378]
22. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, Melhem MF, Yao Z, Zhang J. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 2006; 66: 1311-1318 [PMID: 16705739 DOI: 10.1002/pros.20464]
23. Kirk PS, Koreckij T, Nguyen HM, Brown LG, Snyder LA, Vessella RL, Corey E. Inhibition of CCL2 Signaling in Combination with Docetaxel Treatment Has Profound Inhibitory Effects on Prostate Cancer Growth in Bone. Int J Mol Sci 2013; 14: 10483-10496 [PMID: 23698775 DOI: 10.3390/ ijms140510483]
24. Yoshimura T, Howard OM, Ito T, Kuwabara M, Matsukawa A, Chen K, Liu Y, Liu M, Oppenheim JJ, Wang JM. Monocyte chemoattractant protein-1/CCL2 produced by stromal cells promotes lung metastasis of 4T1 murine breast cancer cells. PLoS One 2013; 8: e58791 [PMID: 23527025 DOI: 10.1371/ journal.pone.0058791]
25. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475: 222-225 [PMID: 21654748 DOI: 10.1038/nature10138]
26. Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, Crisanti MC, Wang LC, Heitjan D, Snyder LA, Albelda SM. CCL2 blockade augments cancer immunotherapy. Cancer Res 2010; 70: 109-118 [PMID: 20028856 DOI: 10.1158/0008-5472. CAN-09-2326]